ArticleAmerican journal of translational research2015
CHRM3 is a novel prognostic factor of poor prognosis in patients with endometrial carcinoma.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Potential mechanisms of Si-Wu-Tang against esophageal squamous cell carcinoma: A machine learning pharmacological study.Medicine · 2026Article
- Article
- Global comparative transcriptomes uncover novel and population-specific gene expression in esophageal squamous cell carcinoma.Infectious agents and cancer · 2023Article
- CHRM3 is a novel prognostic factor of poor prognosis and promotes glioblastoma progression via activation of oncogenic invasive growth factors.Oncology research · 2023Article
- TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2023Article
- RNA-seq profile of African American men with a clinically localized prostate cancer.Prostate international · 2021Article
- Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma.Microorganisms · 2021Review
- Construction of a clinical survival prognostic model for middle-aged and elderly patients with stage III rectal adenocarcinoma.World journal of clinical cases · 2021Article
- RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.Cold Spring Harbor molecular case studies · 2020Article
- Triple-high expression of phosphatase and tensin homolog (PTEN), estrogen receptor (ER) and progesterone receptor (PR) may predict favorable prognosis for patients with Type I endometrial carcinoma.Journal of Cancer · 2020Article
- Article
- Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma.Cancer medicine · 2018Article
- Exploration of DNA methylation markers for diagnosis and prognosis of patients with endometrial cancer.Epigenetics · 2018Article
- High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.OncoTargets and therapy · 2016Article
- The Functional Haplotypes ofBioMed research international · 2016Article
- Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer.BMC cancer · 2015Article
- Comprehensive Analysis of ESRRA in Endometrial Cancer.Technology in cancer research & treatmentArticle
- Neural plasticity of the uterus: New targets for endometrial cancer?Women's health (London, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial carcinoma is the most common gynecologic malignancy. Searching for a new molecule to more accurately predict survival of patients and act as therapy target is urgent. CHRM3 is a major player in many kinds of cancer. The expression level and prognostic value of CHRM3 in endometrial carcinoma remain unclear. In this study, we assayed the expression of CHRM3 in 257 endometrial carcinoma patients by immunohistochemistry. The results showed that CHRM3 expression level was closely correlated with the FIGO stage, vascular invasion and lymphatic metastasis. Although CHRM3 was highly expressed in advanced endometrial carcinoma, multivariate Cox proportional hazards regression analysis showed that CHRM3 expression was not an independent prognostic factor for endometrial carcinoma. Furthermore, to evaluate the prognostic efficiency of CHRM3 in endometrial carcinoma, we compared the sensitivity and specificity of CHRM3 in endometrial carcinoma prognosis by logistic regression. The result showed that CHRM3 combining with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factor alone or combination of risk factors. Thus, CHRM3 potentially offers a clinical value in target therapy for endometrial carcinoma patients.
Indexed as
Identifiers
26175851PMC4494141W980849657What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.